Will AGT103-T work?

Based on its preclinical performance, we are confident in AGT103-T. As a supporting element, the National Institute for Allergy and Infectious Disease (NIAID) replicated our demonstration of HIV clearance in patient blood in vitro during an observational study. We believe these observations bode well for the current phase 1 human trial, and we will provide updates from the phase 1 trial as clinical data becomes available.